Octreotide Is Effective in Acromegaly But Often Results in Cholelithiasis
Authors: W H Daughaday
Journal: Annals of Internal Medicine (1990)

Editorials1 February 1990Octreotide Is Effective in Acromegaly But Often Results in CholelithiasisWilliam H. Daughaday, MDWilliam H. Daughaday, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-112-3-159 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn this issue, Ho and colleagues (1) summarize their considerable experience in treating acromegaly with the long-acting somatostatin analog, octreotide. This agent has a much longer biologic half-life than somatostatin and its effects persist from 4 to 8 hours. Ho and colleagues found that when octreotide was administered twice a day, little additional benefit was gained by increasing each dose from 100 to 500 μg. Serum growth hormone (GH) was lowered more successfully with three doses a day but little benefit was added by increasing the amount of each dose from 100 to 500 μg. Some patients are resistant to...References1. HoWeissbergerMarbachLazarus KAPL. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly: effects of dose and frequency and long-term safety. Ann Intern Med. 1990;112:173-181. LinkGoogle Scholar2. ReubiLandolt JA. The growth hormone responses to octreotide in acromegaly correlated with adenoma somatostatin receptor status. J Clin Endocrinol Metab. 1989;68:844-50. CrossrefMedlineGoogle Scholar3. QuabbePlöckinger HU. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly. J Clin Endocrinol Metab. 1989;68:873-81. CrossrefMedlineGoogle Scholar4. ChristensenWeekeOrskov SJH. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients. Clin Endrocrinol (Oxf). 1987;27:297-306. CrossrefMedlineGoogle Scholar5. TauberBabinTauber JTM. Long term effects of continuous subcutaneous infustion of the somatostatin analog octreotide in the treatment of acromegaly. J Clin Endocrinol Metab. 1989;68:917-24. CrossrefMedlineGoogle Scholar6. JamesWhiteMollerChatterjeeHallKendall-Taylor RMNSKP. Continuous infusion of octreotide in acromegaly. Lancet. 1989;2:1083-7. CrossrefMedlineGoogle Scholar7. ZadikChalewMcCarterMeistasKowarski ZSRMA. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. J Clin Endocrinol Metab. 1985;60:513-6. CrossrefMedlineGoogle Scholar8. ImuraKatoIshikawa HYE. Growth hormone secretion in acromegaly. In: Robbins, Melmed S, eds. Acromegaly: A Century of Scientific and Clinical Progress. New York: Plenum Press; 1987:83-95. CrossrefGoogle Scholar9. ClemmonsVan WykRidgwayKlimanKjellbergUnderwood DJEBRL. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med. 1979;310:1138-42. CrossrefGoogle Scholar10. BarkanBeitinsKelch AIR. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab. 1988;67:69-73. CrossrefMedlineGoogle Scholar11. DaughadayTrivediWinnYan WBHH. Hypersomatotropism in pregnant women, as measured by a human liver radioreceptor assay. J Clin Endocrinol Metab. 1990; [In press]. CrossrefGoogle Scholar12. LembckeCreutzfeldtSchleserEbertShayKoop BWSRCI. Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion. 1987;36:108-24. CrossrefMedlineGoogle Scholar13. FisherRockLevinMalmud REGL. Effects of somatostatin on gallbladder emptying. Gastroenterology. 1987;92:885-90. CrossrefMedlineGoogle Scholar14. MarteauChretienCalmusParcPoupon PYYRR. Pharmacological effects of somatostatin on bile secretion in man. Digestion. 1989;42:16-21. CrossrefMedlineGoogle Scholar15. BodenShimoyama GR. Somatostatinoma. In: Cohen S, Soloway RD, eds. Hormone-Producing Tumors of the Gastrointestinal Tract. New York: Churchill Livingstone; 1985:85-99. Google Scholar16. Comi R. Pharmacology and use in pituitary tumors. In: Gorden P, moderator. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med. 1989;110:35-50. MedlineGoogle Scholar17. JacksonBarnardLamberton ILP. Role of the long-acting somatostatin analogue (SMS 201-995) in the treatment of acromegaly. Am J Med. 1986;81(Suppl 6B): 94-101. CrossrefMedlineGoogle Scholar18. McKnightMcCanceAtkinsonCrothers JDAJ. Changes in glucoase tolerance and development of gall stones during high dose treatment with octreotide for acromegaly. Br Med J. 1989;299:604-5. CrossrefMedlineGoogle Scholar19. WassAndersonBesserDowling JJGR. Gall stones and treatment with octreotide for acromegaly [Letter]. Br Med J. 1989;299:1162-3. CrossrefGoogle Scholar20. BuscailTauberPuel-Bosquet LJC. Gallstones and treatment with octreotide for acromegaly [Letter]. Br Med J. 1989;299:1162. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Washington University School of Medicine St. Louis, Missouri PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByProphylactic Cholecystectomy at Time of Surgery for Small Bowel Neuroendocrine Tumor Does Not Increase Postoperative MorbidityCholelithiasis and acromegaly: therapeutic strategiesUse of octreotide acetate for control of symptoms in patients with islet cell tumorsEffect of chronic octreotide treatment on intestinal absorption in patients with acromegalyGallstones during octreotide therapyLiving with AcromegalyA prospective examination of octreotide-induced gall-bladder changes in acromegalyTherapeutic Use of Somatostatin and Octreotide Acetate in Neuroendocrine TumorsMicrovillus inclusion diseaseMicrovillus inclusion diseaseMiscellaneous hormones 1 February 1990Volume 112, Issue 3Page: 159-160KeywordsAcromegalyBiologicsCholelithiasisGrowth hormoneHalf lifeSomatostatin Issue Published: 1 February 1990 PDF DownloadLoading ...